JMP Securities analyst Jason Butler raised the firm’s price target on Argenx to $471 from $462 and keeps an Outperform rating on the shares. Regulatory progress for VYVGART remains on track for further geographic expansion with multiple global submissions and decisions on approval in primary immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy this year, the analyst tells investors in a research note. The firm sees multiple catalysts in 2024, including full Phase 2 results of empasiprubart in multifocal motor neuropathy.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx reports Q4 EPS ($1.68), consensus ($1.70)
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- ARGX Upcoming Earnings Report: What to Expect?
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024